Evolent Health (EVH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual meeting scheduled for June 4, 2026, with voting open until June 3, 2026, at 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies by May 21, 2026.
Voting can be done online, by mail, or in person at the virtual meeting.
Voting matters and shareholder proposals
Election of ten directors, each recommended by the board for approval.
Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote to approve executive compensation for 2025.
Approval of amendment to the 2015 Omnibus Incentive Compensation Plan.
Other business may be addressed as appropriate during the meeting.
Board of directors and corporate governance
Board recommends all ten director nominees for election at the annual meeting.
Latest events from Evolent Health
- Q2 2026 revenue up to $653M, guidance raised, and oncology partnership announced.EVH
Q2 2026 - Revenue up 2.6% to $496.2M, net loss narrows, and new contracts support future growth.EVH
Q1 2026 - Proxy covers director elections, auditor ratification, compensation, and equity plan amendment.EVH
Proxy filing - Strong pipeline, conservative guidance, and focus on profitability drive growth outlook.EVH
Oppenheimer 36th Annual Healthcare MedTech & Services Conference - 2026 guidance projects 30–33% revenue growth and margin expansion, led by new contracts.EVH
Q4 2025 - Stable specialty trends, new protections, and divestiture proceeds drive growth and deleveraging.EVH
Piper Sandler 37th Annual Healthcare Conference - AI-driven specialty care and recent acquisitions fuel growth toward a $300M EBITDA target.EVH
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 - Q2 revenue up 37.9% to $647.1M, net loss narrows, new contracts and Machinify acquisition completed.EVH
Q2 2024 - Q1 2025 revenue fell and losses widened, but new agreements and guidance reaffirm growth prospects.EVH
Q1 2025